Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Canadian biotech firm Gemin X has begun a phase I clinical trial of its investigational anti-cancer candidate in patients with refractory solid tumors and lymphomas.
Subscribe to our email newsletter
The compound, GMX1777, was licensed worldwide from LEO Pharma. The open-label, dose-escalation trial will enroll approximately 18-24 patients with refractory solid tumors and lymphomas at a single center.
Patients will receive infusions of GMX1777 as a single agent in 3-week cycles. The objectives of this study are to determine the toxicity and pharmacokinetic profile of the compound, document any anti-tumor activity, and establish a recommended dose and schedule for phase II trials.
Under the terms of the agreement, Gemin X has an exclusive license to develop and market GMX1777 worldwide. In return, LEO Pharma has received an upfront payment, and is eligible to receive payments upon achievement of certain development and regulatory milestones, in addition to royalties on net sales. Specific financial terms of the deal were not disclosed.